From a9c401d4844d8a961624c7de4efae535c60741db Mon Sep 17 00:00:00 2001 From: borja Date: Wed, 30 Oct 2024 15:36:52 +0100 Subject: [PATCH] Auto saved by Logseq --- pages/InCORNTD 2025___Application.md | 2 +- 1 file changed, 1 insertion(+), 1 deletion(-) diff --git a/pages/InCORNTD 2025___Application.md b/pages/InCORNTD 2025___Application.md index 184fab77..8dc2d843 100644 --- a/pages/InCORNTD 2025___Application.md +++ b/pages/InCORNTD 2025___Application.md @@ -3,7 +3,7 @@ - #+BEGIN_VERSE **Description**: The fixed-dose coformulation (FDC) of albendazole and ivermectin is the result of more than 10 years of innovations carried out by African and European organizations working through public-private partnerships. - This orodispersible, mango-flavoured tablet has already demonstrated safety and efficacy against soil-transmitted helminths in a 2022/2023 phase II/III pivotal trial. The results are already accepted for publication in Lancet Infectious Diseases and are currently under evaluation by the European Medicines Agency (EMA) under the EU-M4All procedure and Ghana's FDA for registration. + This orodispersible, mango-flavoured tablet has already demonstrated safety and efficacy against soil-transmitted helminths in a 2022/2023 phase II/III pivotal trial. The results are already accepted for publication in Lancet Infectious Diseases and are currently being evaluated by the European Medicines Agency (EMA) under the EU-M4All procedure, and Ghana's FDA for registration. The fixed-dose combination of albendazole and ivermectin provides a novel approach to mass drug administration campaigns that simplifies logistics while providing control abilities for more parasites. It allows for a more targeted approach #+END_VERSE